As of 2023, John Evans has shown considerable involvement with Beam Therapeutics through significant stock holdings, reflecting his commitment to the company. His wealth reached $961,652 from vested stock this year, despite an overall dip in the company's value. Notably,...

As of 2023, John Evans has shown considerable involvement with Beam Therapeutics through significant stock holdings, reflecting his commitment to the company. His wealth reached $961,652 from vested stock this year, despite an overall dip in the company's value. Notably, his stock compensation structure aligns with performance goals; he received no stock vested outside of cash bonuses this year, showcasing a strategic focus on immediate cash incentives rather than long-term capital gains. This pattern wasn't always the case—last year he also saw a substantial vested stock value totaling $2.2 million. His holdings exemplify careful risk management without speculative trading. Overall, Evans' portfolio indicates he is heavily invested in Beam's success, which has clear implications for the company's future.